I. N. Olver

650 total citations
17 papers, 504 citations indexed

About

I. N. Olver is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, I. N. Olver has authored 17 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Surgery and 3 papers in Molecular Biology. Recurrent topics in I. N. Olver's work include Cancer Treatment and Pharmacology (4 papers), Nausea and vomiting management (3 papers) and Testicular diseases and treatments (2 papers). I. N. Olver is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Nausea and vomiting management (3 papers) and Testicular diseases and treatments (2 papers). I. N. Olver collaborates with scholars based in Australia, New Zealand and United States. I. N. Olver's co-authors include Guy C. Toner, Euan Walpole, Alan S. Coates, Peter Hersey, Richard Kefford, David Thomson, P. Grantley Gill, Michael Friedländer, R. John Simes and James F. Bishop and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

I. N. Olver

17 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. N. Olver Australia	11	242	171	107	69	66	17	504
Reinhold Bergstr�m Sweden	8	323 1.3×	117 0.7×	73 0.7×	37 0.5×	58 0.9×	9	679
De Haas Netherlands	9	164 0.7×	170 1.0×	68 0.6×	27 0.4×	156 2.4×	19	562
Bohdan Huszno Poland	14	143 0.6×	266 1.6×	80 0.7×	33 0.5×	44 0.7×	61	677
Deborah Cruickshank Australia	12	99 0.4×	191 1.1×	307 2.9×	94 1.4×	60 0.9×	17	724
Yoo Seok Kim South Korea	13	195 0.8×	133 0.8×	91 0.9×	32 0.5×	56 0.8×	39	558
Jean Pierre Droz France	15	235 1.0×	574 3.4×	217 2.0×	137 2.0×	127 1.9×	24	1.0k
Tarık Salman Türkiye	16	314 1.3×	109 0.6×	107 1.0×	83 1.2×	84 1.3×	67	585
Donald Poon Singapore	10	314 1.3×	84 0.5×	103 1.0×	120 1.7×	90 1.4×	14	774
Josefa Terrasa Spain	11	116 0.5×	154 0.9×	88 0.8×	14 0.2×	77 1.2×	31	420
Victor J. Lanzotti United States	13	463 1.9×	256 1.5×	272 2.5×	184 2.7×	105 1.6×	17	1.0k

Countries citing papers authored by I. N. Olver

Since Specialization

Citations

This map shows the geographic impact of I. N. Olver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. N. Olver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. N. Olver more than expected).

Fields of papers citing papers by I. N. Olver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. N. Olver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. N. Olver. The network helps show where I. N. Olver may publish in the future.

Co-authorship network of co-authors of I. N. Olver

This figure shows the co-authorship network connecting the top 25 collaborators of I. N. Olver. A scholar is included among the top collaborators of I. N. Olver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. N. Olver. I. N. Olver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Olver, I. N., Peter Grimison, Mark D. Chatfield, et al.. (2012). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer. 21(6). 1561–1568. 26 indexed citations

Olver, I. N., Michael Byrne, Euan Walpole, et al.. (2007). Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. European Journal of Cancer. 43(12). 1829–1832. 13 indexed citations

Borg, Matthew, Eric Yeoh, Melissa Bochner, et al.. (2007). Feasibility study on the MammoSite in early‐stage breast cancer: Initial experience. Australasian Radiology. 51(1). 53–61. 3 indexed citations

Toner, Guy C., Michael Boyer, Michael Jones, et al.. (2001). Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. The Lancet. 357(9258). 739–745. 75 indexed citations

Bishop, James F., Joanna Dewar, Guy C. Toner, et al.. (1997). A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer : Preliminary results. Seminars in Oncology. 24(5). 6 indexed citations

Beller, Elaine, Martin Tattersall, Thomas Lumley, et al.. (1997). Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial. Annals of Oncology. 8(3). 277–283. 63 indexed citations

Michael, Michalis, et al.. (1997). Phase I Dose Intensification Study of 2-Weekly Epirubicin with GM-CSF in Advanced Cancer. American Journal of Clinical Oncology. 20(3). 259–262. 1 indexed citations

Boyer, Michael, John Zalcberg, I. N. Olver, et al.. (1997). Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer. Annals of Oncology. 8(5). 485–489. 7 indexed citations

Bishop, James F., Joanna Dewar, Guy C. Toner, et al.. (1997). Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.. PubMed. 11(4 Suppl 3). 19–23. 28 indexed citations

10.

Millward, Michael, J. Bishop, Michael Friedländer, et al.. (1996). Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 14(1). 142–148. 61 indexed citations

11.

Phillips, Kelly‐Anne, Michael Friedländer, I. N. Olver, et al.. (1995). Australasian multicentre phase II study of paclitaxel (Taxol*) in relapsed ovarian cancer. Australian and New Zealand Journal of Medicine. 25(4). 337–343. 10 indexed citations

12.

Coates, Alan S., David Thomson, Peter Hersey, et al.. (1993). Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. European Journal of Cancer. 29(12). 1731–1734. 118 indexed citations

13.

Olver, I. N.. (1992). Methodology in Anti-Emetic Trials. Oncology. 49(4). 269–272. 11 indexed citations

14.

Wolf, M., et al.. (1985). NON‐HODGKIN'S LYMPHOMA INVOLVING THE CENTRAL NERVOUS SYSTEM. Australian and New Zealand Journal of Medicine. 15(1). 16–21. 22 indexed citations

15.

Bishop, James F., I. N. Olver, Jane Matthews, et al.. (1984). Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.. Journal of Clinical Oncology. 2(6). 691–695. 43 indexed citations

16.

Olver, I. N., et al.. (1983). COMPLETE REMISSION IN EXTRAGONADAL SEMINOMA PRIMARILY TREATED WITH CHEMOTHERAPY AND RESTAGED BY RETROPERITONEAL NODAL DISSECTION. Australian and New Zealand Journal of Surgery. 53(3). 277–280. 1 indexed citations

17.

Olver, I. N., Garry Jennings, Alex Bobik, & Murray Esler. (1980). Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.. BMJ. 281(6235). 275.2–276. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact